Background Data are needed to inform the positioning of biologic therapy in the treatment of
moderate-to-severe Crohn's disease, both first line and after previous biologic exposure. We …

The term inflammatory bowel disease (IBD) refers principally to two major categories of
chronic relapsing inflammatory intestinal disorders: Crohn's disease (CD) and ulcerative …

Summary Background The Crohn's disease exclusion diet (CDED) with partial enteral
nutrition is effective for induction of remission in children with mild-to-moderate Crohn's …

Methods This document presents the official recommendations of the AGA on the medical
management of moderate to severe luminal and fistulizing CD in adults. This guideline …

Background Biomarkers of intestinal inflammation, such as faecal calprotectin and C-
reactive protein, have been recommended for monitoring patients with Crohn's disease, but …

Importance An increased risk of lymphoma has been reported among patients receiving
thiopurines for inflammatory bowel disease (IBD). The risk of lymphoma associated with anti …

Various therapeutic advances have led to a paradigm shift in the clinical management of
patients with IBD. The introduction of immunosuppressive (such as azathioprine) and …

OBJECTIVES: The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE)
program was initiated by the International Organization for the Study of Inflammatory Bowel …

Background & Aims The IM-UNITI study and long-term extension (LTE) evaluated the long-
term efficacy, safety, and immunogenicity of subcutaneous ustekinumab maintenance …

Crohn's disease and ulcerative colitis have emerged as global diseases. They affect over 2
million individuals in the North America, 3.2 million in Europe, and millions more worldwide …